Evidence map›Paper›PMID 41837732›Full record

ReviewFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026

Targeting Arterial Dysfunction in Cardiovascular Disease Using Stem Cell-Based Therapies.

Yun-Yu Ma, Shu-Yao Zhu, Yi Song

Abstract readReview
In one paragraph

Review in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yun-Yu MaDepartment of Cardiology, Fuwai Yunnan Cardiovascular Hospital, Kunming, China.
Shu-Yao ZhuDepartment of Anesthesiology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yi SongDepartment of Cardiology, Fuwai Yunnan Cardiovascular Hospital, Kunming, China.ORCID https://orcid.org/0000-0003-1651-6039

Funding

Fuwai Yunnan Cardiovascular Hospital 2025YFKT-PY-01
6 · The paper itself

Abstract

Arterial regeneration represents a critical frontier in cardiovascular medicine, as progressive endothelial dysfunction, maladaptive vascular smooth muscle cell (SMC) plasticity, and chronic inflammation drive atherosclerosis, restenosis, and vascular aging. Although current therapies such as pharmacological risk-modifying therapies and interventional revascularization procedures mitigate the risk and delay the progression, they are still unable to restore vascular integrity. Stem cell-based strategies were initially conceived to replace the lost vascular cells directly; however, accumulating evidence indicates their therapeutic benefits arise from paracrine mechanisms including regulation of endothelial repair, modulation of SMC phenotypic switching, and attenuation of inflammatory signaling. This paradigm shift has expanded the regenerative landscape to encompass endothelial progenitor cells, mesenchymal stromal cells, induced pluripotent stem cell-derived vascular lineages, and engineered extracellular vesicle platforms. Parallel advances in biomaterials, mechanically tuned scaffolds, and hybrid cell-matrix constructs provide more physiologic microenvironments for vascular repair and enhance the retention, potency, and safety of regenerative therapies. Concurrently, gene editing, metabolic reprogramming, and hypoxic preconditioning further refine the functional capacity of stem cell-derived products, enabling targeted correction of endothelial instability and improving regulation of vascular remodeling. Integration of multi-omic profiling and high-resolution vascular phenotyping now positions the field to align regenerative strategies with patient-specific determinants of disease. This review integrates current knowledge on stem cell-mediated endothelial regeneration, SMC phenotype regulation, and bioengineered vascular interventions, and examines emerging precision-medicine frameworks poised to guide next-generation therapies that link mechanistic principles with translational progress to enable durable restoration of arterial structure and function, and long-term vascular health, thereby providing a theoretical basis for future research.

Indexed as

ArteriesCardiovascular DiseasesStem Cell TransplantationAnimalsEndothelial Progenitor CellsHumansMuscle, Smooth, VascularRegenerationblood vessel regenerationcellular metabolismendotheliumphenotypic plasticitystem cell transplantationvascular smooth muscle cells

Identifiers

PMID41837732
PMCPMC12990847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.